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The Kv1.3 channel is important in the activation and function of effector memory T cells. Recently, specific
blockers of the Kv1.3 channel have been developed as a potential therapeutic option for diverse autoimmune
diseases. In psoriatic lesions, most lymphocytes are memory effector T cells. The aim of the present study was to
detect the expression of Kv1.3 channels in these cells in psoriatic lesions as well as in human psoriasiform skin
grafts using the severe combined immunodeficient (SCID) mouse model. Histological and immunohistoche-
mical staining for Kv1.3 expression and various inflammatory markers was performed in sections obtained from
six psoriatic patients and 18 beige-SCID mice with psoriasiform human skin grafts. Six grafted mice were treated
with Stichodactyla helianthus neurotoxin (ShK), a known Kv1.3 blocker. The results showed an increased
number of Kv1.3þ cells in the psoriatic skin as well as in the psoriasiform skin grafts as compared with normal
skin and normal skin grafts. Injections of ShK showed a marked therapeutic effect in three of six psoriasiform
skin grafts. A significantly decreased number of Kv1.3þ cells was observed in the responders compared with
the control grafts. This pilot study, although performed in a small number of mice, reveals the possible
beneficial effect of Kv1.3 blockers in psoriasis patients.
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INTRODUCTION
The Kv1.3 channel is one of many memory Kþ channel
genes and in T cells has distinct biological and pharmaco-
logical properties (Beeton et al., 2006). It is expressed by
human T lymphocytes that are involved in proliferation and
cytokine secretion (Beeton et al., 2006). All human T cells
express roughly 300 Kv1.3 channels per cell, and upon
activation, effector memory T cells increase the expression of
the Kv1.3 channel four- to fivefold (Beeton et al., 2006).
Kv1.3 is physically coupled through a series of adaptor
proteins to the T-cell receptor signaling complex, and it traffics
to the immunological synapse during antigen presentation (Panyi
et al., 2004; Beeton et al., 2006). Kv1.3 and KCa3.1, another
K channel, regulate membrane potential and calcium signaling of
T cells. Calcium entry through the calcium release-activated
calcium channel is promoted by potassium efflux through the
Kv1.3 and KCa3.1 potassium channels (Matheu et al., 2008).
Recently, specific blockers of the Kv1.3 channel have been
developed as a therapeutic option for diverse autoimmune
diseases (Wulff et al., 2003a, b). Indeed, these blockers were
found to be effective in various animal models of autoimmune
diseases, such as multiple sclerosis, type 1 diabetes mellitus,
rheumatoid arthritis, and allergic contact dermatitis
(Azam et al., 2007; Beeton et al., 2001b, 2005, 2006, 2008).
Blockade of Kv1.3 channels in effector memory T cells
suppressed calcium signaling, cytokine production (IFN-g,
IL-2), and cell proliferation (Wulff et al., 2003a, b; Chandy
et al., 2004; Beeton et al., 2006). Furthermore, Azam et al.
(2007) recently demonstrated that Kv1.3 blockers could
suppress allergic contact dermatitis in a rat model by reducing
the production of various cytokines, including IL-17, that
represent the Th17 subset, attracting increasing attention to
inflammatory processes including psoriasis.
Kv1.3 blockers do not affect the homing to and motility
within lymph nodes of naive and central memory T cells,
most likely because these cells express the KCa3.1 channel
and are therefore protected from the effects of Kv1.3
blockade (Matheu et al., 2008). Thus, the notion is that it
is possible to selectively suppress effector memory T cells
with a Kv1.3-specific blocker and thereby ameliorate many
autoimmune diseases without compromising the protec-
tive immune response. The differences in potassium channel
phenotype between naive, central memory, and effector
memory T cells, together with the selective suppres-
sive effects of Kv1.3 inhibitors on effector memory T cells,
make Kv1.3 an attractive therapeutic target without the usual
side effects observed after broad-range immunosuppressive
therapy.
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In psoriatic lesions, most lymphocytes are memory effector
(CD4þCD45ROþ and CD8þCD45ROþ ) T cells. It has
been suggested that these cells are indeed important in the
pathogenesis of psoriasis (Ellis and Krueger, 2001). Given that
memory effector T cells express high levels of Kv1.3, we find
it of interest to detect the expression of Kv1.3 channels in
these cells in psoriatic lesions as well as in human psoriasi-
form skin grafts on the severe combined immunodeficient
(SCID) mouse model. Nickoloff et al. (1995, 1999) and our
group (Gilhar et al., 2002, 2006) have shown that T cells
bearing natural killer (NK) receptors were precisely and
strongly targeted as new putative pathogenic immunocytes in
psoriasis and were shown to induce psoriatic plaques in SCID
mice. Uninvolved skin from psoriasis patients as well as
normal volunteers can be induced to express psoriasiform
features when injected intradermally with activated NK-like
cells. Thus, in the present study we addressed two questions.
The first was whether there would be an overexpression of
Kv1.3 channels by lesional cells in psoriasis as well as in the
grafted SCID mice, as was suggested in a recent abstract
(Raychaudhuri et al., 2009). Second, we evaluated the
therapeutic effect of Kv1.3 blockers on the development of
psoriasis in the SCID mice.
RESULTS
Two sets of experiments were performed. The aim of the first
was to determine the number of Kv1.3þ cells in psoriatic
dermis; in the second one, we investigated the functional
significance of Kv1.3 in psoriasis by administering a Kv1.3
blocker to psoriasiform human skin grafts on SCID mice.
Experiment 1: the histological and immunohistochemical
features of psoriasis and psoriasiform human skin grafts in a
SCID mouse model
Normal human skin transplanted onto 12 beige-SCID mice
was treated with allogeneic psoriatic NK-like cells as
described previously (Gilhar et al., 2006). All grafts in the
present study demonstrated features of psoriasis and were
basically similar to the histological features of biopsies
obtained from six psoriatic patients that exhibited hyperker-
atosis, parakeratosis, Munro microabscess, and epidermal
thickening (acanthosis), with lack of the granular layer.
Elongation of rete ridges, edema, vascular dilatation, and
dilated tortuous blood vessels in the dermal papilla along
with perivascular inflammatory cell infiltrates (Figure 1a–c)
were also observed. Immunohistochemical staining showed a
striking expression of Kv1.3þ cells (Figure 2) in specimens of
PBS-treated mice
Non-responders
ShK-treated mice
Responders
Figure 1. Histological features of all natural killer (NK)-like cell–treated grafts injected with either phosphate-buffered saline (PBS) or Stichodactyla
helianthus neurotoxin (ShK). Treated with PBS, a–c: (a) psoriasiform hyperplasia with a thin suprapapillary plate. There are parakeratosis, hypogranulosis, and
neutrophils in the upper spinous layer in the corneal cell layer. (b) Edema and dilated tortuous blood vessels in the dermal papilla. (c) Subcorneal pustule present
in the upper spinous cell layer in a subcorneal location. Treated with ShK, nonresponders group, d–f: (d) as can be seen, psoriatic features were observed in all
three grafts. In f, a typical Munro microabscess can be seen. Treated with ShK, responders group, g–i: the figures show orthokeratosis and some residual
acanthosis. The mononuclear cell infiltrates in the papillary dermis are minimal. Disappearance of most of the psoriasiform features in three of six grafts was
observed and the epidermis appears normal, whereas in the papillary dermis there is a mild to moderate perivascular mononuclear cell infiltrate. Bar¼100 mm.
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psoriatic lesion (15.1±5.20 vs. 0.28±0.64 in normal skin,
Po0.001) (Figure 3). This expression by Kv1.3 cells was
detected along the upper part of the dermis, mostly along the
papillary area, and in the lower parts of the epidermis
(Figure 2). In normal control biopsies, only a few, if any, cells
were observed. These Kv1.3þ cells were accompanied by
an abundance of characteristic cellular and inflammatory
markers, such as CD3þ cells (22.9±7), tumor necrosis
factor (TNF)-a (12.4±3.3), and IFN-g (12.8±3.6), and a
much smaller quantity of CD16 (6.7±2.2), CD56 (4.5±2.3),
and CCR7 (5.9±2.3) cells (Table 1). More Kv1.3 channels
and fewer CCR7þ cells were detected in the lesional
psoriatic skin (15.1±5.2 and 5.9±2.3) as compared
with the psoriasiform skin grafts (8.5±2.51 and 7.4±3.4,
Po0.002, Po0.04, respectively). Still, a significant increase
in the number of Kv1.3 cells was noted in psoriasiform
skin grafts as compared with normal skin grafts (8.5±2.51 vs.
0.65±0.5, Po0.001). Many more TNF-aþ (21±5.5) cells
were detected in the psoriasiform grafts than in the psoriatic
skin (12.4±3.3, Po0.001). In contrast, many more CD16
cells were detected in the psoriatic skin (6.7±2.2) than
in the skin grafts (4.3±2.3, Po0.04). A similar pattern of
distribution of the remaining cellular markers was observed,
along the dermis of the psoriasiform human skin grafts
and the psoriatic lesions, with respect to the number
of CD3þ (26.2±9.9 and 22.9±7, respectively), IFN-gþ
(12.3±7.8 and12.8±3.6), and CD56þ (3.1±1and 4.5±2.3,
respectively) cells.
Experiment 2: therapeutic effect of ShK on psoriasiform
human skin in a SCID mouse model
Twelve SCID mice, grafted with normal human skin and
injected with allogeneic psoriatic NK cells, were used in this
study. Six mice were treated with the Kv1.3 blocker
(Stichodactyla helianthus neurotoxin, ShK); the remaining
six mice served as a control group and were treated with
phosphate-buffered saline (PBS). All six control grafts showed
histological feature of psoriasiform, as observed before.
Among those treated with ShK, three of six grafts showed a
marked therapeutic effect with normal appearance of the skin
grafts (Figure 1g–i). Indeed, the clinical appearance of the
three nonresponders’ grafts revealed persistent scale and
thickened skin in contrast to the responders’ grafts, which
exhibited normalization of the skin grafts’ appearance. The
histological evaluation of the nonresponders’ grafts con-
firmed their phenotype, including absence of the granular
layer, increased epidermal thickness, elongation of rete
ridges with blunted ends, and intralesional presence of
mononuclear cells. Thus, there was no beneficial effect in
those nonresponders’ grafts (Figure 1d–f). The responders’
grafts, however, revealed a complete recovery, with only a
mild mononuclear infiltrate along the upper part of the
dermis (Figure 1g–i). Indeed, the epidermal thickening of the
three responders’ grafts was significantly lower than in the
nonresponders’ grafts (589±42.5 vs. 1501±277.1, Po0.05).
Immunohistochemical staining revealed more Kv1.3þ cells
in the control PBS-treated group (9.4±2.8) than in the
ShK-treated group (5.83±4.16), but the difference was
not significant (Figures 2 and 3). Similarly, more CD3þ ,
TNF-aþ , and IFN-gþ cells were detected in the PBS-treated
grafts (27.83±5.38, 21.83±8.93, and 12.3±3) than in
the ShK group (19.33±13.33, 17.16±9.02, and 9.33±7.9,
respectively) (Figure 4), but again without statistically significant
differences. Still, looking at the three positive-responder grafts
in the ShK-treated group, significantly decreased numbers
of Kv1.3þ (3±1.73) (Figure 3), CD3þ (8±6.55), TNF-aþ
(10±2), and IFN-gþ (2.3±1.52) cells were observed in
the responders’ as compared with the nonresponders’
grafts (8.67±4.04, 30.67±4.04, 24.31±6.75, and 16.3 ±3,
Po0.024, Po0.046, Po0.05, and Po0.05, respectively)
(Table 2, Figure 4).
Phenotypic characterization of cells before and after culture
After activation of peripheral blood mononuclear cells
(PBMCs) with a high dose of IL-2 (see Materials and
Methods), an increase of Kv1.3 expression was observed
(data not shown).
DISCUSSION
Kv1.3 voltage-gated potassium channels maintain the mem-
brane potential of effector memory T cells, which are
important mediators in various autoimmune diseases (Wulff
et al., 2003a, b; Beeton et al., 2006). Potassium channels
have a critical role in maintaining the electrochemical
Psoriatic lesion NK cells injected and PBS
NK cells injected and ShKNormal human skin
Figure 2. Immunohistochemical staining for Kv1.3 of normal skin, psoriatic
lesions, and natural killer (NK)-like cell–treated grafts combined with either
phosphate-buffered saline (PBS) or Stichodactyla helianthus neurotoxin
(ShK). (a) Psoriatic skin with positive expression of Kv1.3 by mononuclear
cells in a dermal papilla, versus (b) normal skin, demonstrates a complete
negative staining of Kv1.3. (c) NK-like-treated graft combined with PBS shows
positive staining of mononuclear cells in the dermal papilla and in the basal
cell layer, whereas treatment of the grafts with NK-like cells combined with
Kv1.3 blocker (ShK) leads to complete disappearance of these cells in the
responder grafts; thus, (d) there are no Kv1.3þ cells present in the responder
ShK-treated skin graft. Bar¼ 100mm.
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gradient required for sustained calcium entry in the time
frame required for activation and effector function (Rus et al.,
2005). Thus, Kv1.3 regulates membrane potential and Ca2þ
signaling in human T cells, and its expression is increased
four- to fivefold in activated CD4þ and CD8þ effector
memory T cells. In contrast, human naive/central memory
T cells upregulate the calcium-activated KCa3.1 channel to
regulate membrane potential and Ca2þ signaling in the
activated state (Beeton et al., 2001a; Wulff et al., 2003a, b;
Chandy et al., 2004). This enhanced Kv1.3 expression is
likely to promote calcium signaling necessary for activated
memory cells to perform their effector functions. Previous
studies demonstrated that disease-associated autoreactive
T cells in type 1 diabetes mellitus, multiple sclerosis, and
rheumatoid arthritis are mainly CCR7, Kv1.3þ , effector
memory T cells, and this phenotype could serve as an
important marker to distinguish autoreactive T cells between
patients and control subjects (Beeton et al., 2006). The results
of this study demonstrated an extensive positive staining for
these Kv1.3 channels on lymphocytes in psoriatic lesions
tissue. Most of these Kv1.3þ cells were CCR7, which
strongly suggests that the majority of the inflammatory
infiltrate in psoriatic skin are indeed activated effector
memory T cells that have probably undergone repeated
antigen stimulation in vivo during the course of the disease.
This observation is in agreement with a recent description by
Raychaudhuri et al. (2009) that showed an increased number
of Kv1.3 infiltrating T cells in psoriatic dermis as well as in
psoriatic arthritis synovial tissue. In our study, Kv1.3 channels
were also expressed by T-cell infiltrates along the dermis of
the psoriasiform SCID mouse model, but to a significantly
smaller extent than in pure psoriasis obtained from patients
(Po0.002). Furthermore, a significantly increased number of
CCR7þ cells was observed in the psoriasiform grafts as
compared with the pure psoriatic lesions, indicating a
reduction of the number of effector memory T cells (CCR7)
in the grafts versus pure psoriasis. This human skin
transplantation model was originally developed using human
psoriatic skin engrafted onto SCID mice, resulting in psoriasi-
form lesions involving T lymphocytes, monocytes, macro-
phages, and dendritic cells (Nickoloff et al., 1995). Later, the
model was further refined to use normal human skin
engrafted onto beige-SCID mice (which lack murine NK
cells) and injection of allogeneic psoriatic NK-like cells that
had been stimulated in culture with IL-2 (Nickoloff et al.,
1999; Gilhar et al., 2002, 2006). The present study revealed,
by flow cytometric analysis, an upregulated expression of
Kv1.3 by the PBMCs following incubation with the high level
of IL-2. The upregulation of Kv1.3 was present mainly in
CD3þ T cells. This analysis confirmed a previous study
demonstrating that a high Kv1.3 pattern was not detected in
PBMCs because autoreactive T cells are infrequent in the
circulation (Beeton et al., 2006).
The interaction of NK-like cells and the surrounding
myeloid cell populations (for example, monocytes and
neutrophils) with human keratinocytes allows the assessment
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Figure 3. Kv1.3 channel expression in psoriatic lesions versus natural killer (NK)-like cell–treated grafts. A significantly increased number of Kv1.3þ cells
is observed in psoriatic lesions as compared with normal skin grafts, which developed a psoriasiform appearance following treatment with NK-like cells.
A nonstatistical significance was found between grafts treated with PBS and those treated with Stichodactyla helianthus neurotoxin (ShK). A comparison
between the ShK group responders (three out of six) and the nonresponders demonstrates a significant decrease in Kv1.3 in the responder group.
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of TNF-a and IFN-g production, as well as keratinocyte
expression of activation markers (Gilhar et al., 2006). The
normal donor skin sections xenografted onto beige-SCID
mice and treated with psoriatic patient NK cells developed
psoriasiform features. The significantly higher expression
of Kv1.3 by the dermal psoriatic skin as compared with
the psoriasiform skin grafts clearly indicates the presence of
many more effector memory T cells within psoriatic lesions,
probably because of stronger and continuous antigenic
stimulation. Still, the study showed that the numbers of
Kv1.3þ cells within the psoriasiform grafts are significantly
higher than in normal skin grafts, which are almost empty of
these sorts of channels (9.4±2.8 vs. 0.65±0.5, Po0.001)
and are probably sufficient to induce the development of
psoriasiform features. A similar pattern of distribution has
been observed with respect to the numbers of CD3þ ,
CD56þ , and IFN-gþ cells, in both psoriatic skin and
psoriasiform grafts. The finding of Kv1.3þ and CCR7 cells
in psoriatic lesions might open a new area of treatment for
psoriasis. Indeed, previous studies revealed that blockade of
the Kv1.3 channel suppresses antigen-driven proliferation
and cytokine production (Wulff et al., 2003a, b), leading to
amelioration of various autoimmune processes in animal
models (Koo et al., 1999; Beeton et al., 2001a, b; Valverde
et al., 2004; Matheu et al., 2008). In the present study, we
looked at the effect of blocking Kv1.3 on the development of
psoriasis, which was not looked at previously. It has been
observed that ShK, which is a potent and selective blocker of
Kv1.3, is a potential therapeutic option for autoimmune
diseases (Pennington et al., 1996; Wulff et al., 2003a, b;
Norton et al., 2004; Matheu et al., 2008). Indeed, in our study
ShK effectively suppressed the development of psoriasiform
features in three of six human grafts. ShK exerts its effect
by reducing the infiltration of T cells and thus also the
production of the inflammatory cytokines IFN-g and TNF-a.
A significant reduction of TNF-aþ and IFN-gþ cells was
detected in the responders’ grafts as compared with those of
the nonresponders (Po0.02 and Po0.05, respectively).
Table 1. Distribution of inflammatory cells in
psoriatic lesions versus NK-like cell–treated grafts1
Group
Marker NK-like cell–treated grafts Psoriatic lesions P-value
CD3 26.3±9.96 (n=8) 23.0±7.33 (n=10) 0.372
Kv1.3 8.5±2.51 (n=11) 15.1±5.20 (n=8) 0.002
CCR7 7.4±3.39 (n=11) 5.9±2.36 (n=8) 0.043
IFN-g 12.3±7.8 (n=9) 12.8±3.65 (n=8) 0.8
TNF-a 21.3±5.53 (n=10) 12.5±3.33 (n=8) 0.001
CD56 3.1±1.10 (n=8) 4.6±2.31 (n=7) 0.135
CD16 4.3±2.33 (n=8) 6.7±2.21 (n=6) 0.080
Abbreviations: NK, natural killer; TNF, tumor necrosis factor.
1The positive cells in the dermal compartment were counted in an area of
0.015mm2.
Psoriatic lesion
CD3
IFN-γ
TNF-α
NK-like-treated graft/PBS NK-like-treated graft/ShK
Figure 4. Immunohistochemical staining of psoriatic lesions, natural killer (NK)-like cell–treated grafts combined with either phosphate-buffered saline
(PBS) or Stichodactyla helianthus neurotoxin (ShK). The psoriatic lesions and the NK-like-treated grafts with the psoriasiform features demonstrate massive
infiltrates of CD3þ , IFN-gþ , and tumor necrosis factor (TNF)-aþ cells along the upper part of the dermis. However, ShK administration led to recovery of the
epidermis in the responder’s grafts (three out of six). Dense infiltrates of these markers were noted in both the psoriatic and the NK-like-treated grafts,
whereas treatment of grafts with the Kv1.3 blocker induced a striking decrease of CD3 and IFN-g and TNF-a expression. Bar¼ 100mm.
Table 2. Distribution of inflammatory cells in
psoriasiform skin grafts treated with ShK1
Marker Responders Non-responders P-value
Kv1.3 3.0±1.73 8.6±4.00 0.02
CD3 8.0±6.56 30.67±4.04 0.05
TNF-a 10.0±2.00 24.3±6.75 0.05
IFN-g 2.3±1.53 16.33±3.05 0.05
Abbreviations: ShK, Stichodactyla helianthus neurotoxin; TNF, tumor
necrosis factor.
1The positive cells in the dermal compartment were counted in an area of
0.015mm2.
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The treatment with ShK did not induce a complete
recovery of the psoriasiform grafts. This could be attributed
to the fact that TNF-a can also be produced by keratinocytes
(Gilhar et al., 2006), Langerhans cells (Wang et al., 1999),
and mast cells (Biedermann et al., 2000), which are probably
not affected by ShK.
In summary, our study demonstrated high expression
of Kv1.3 channels in psoriasis and psoriasiform grafts of
the SCID mouse model. The Kv1.3 channel showed more
specificity for autoreactive T cells than any molecular target
expressed on all T cells. Although blocking Kv1.3 has been
shown to be quite effective in several autoimmune animal
models, this is the first study, to the best of our knowledge, to
show the effect in psoriasis, a presumed T-cell-mediated
autoimmune condition. Although this is a small study, in
which three of six mice responded (50%), we believe that
these encouraging results should promote more large-scale
studies to confirm the biological effects of Kv1.3 blocker
in psoriasis. Small-molecule Kv1.3 inhibitors would have
several advantages over other immunotherapeutics, being
less expensive to produce and easier to ship and store,
and their oral bioavailability and relatively short half-lives
would allow more rapid termination of therapy if adverse
effects were observed (Beeton et al., 2006). Although more
experiments are needed to evaluate Kv1.3 blockers in
rodents, ShK might represent a possible new therapeutic
agent in psoriasis.
MATERIALS AND METHODS
Animals
Thirty-five C.B-17/IcrHsd-scid-bg (beige-SCID) mice (Harlan Labora-
tories, Jerusalem, Israel), 2–3 months of age, were used in this study.
The mice were raised in the pathogen-free animal facility of the B.
Rappaport Faculty of Medicine, Technion–Israel Institute of Techno-
logy. Animal care and research protocols were in accordance with
institutional guidelines and were approved by the institutional
committee on animal use.
Patients
After the study had received the approval of the institutional ethics
committee, psoriatic patients were enrolled. All patients had classic
plaque psoriasis, and none was being treated. Lesional psoriatic skin
was obtained from the thighs of each patient using electrical
dermatome (Brown 666 Dermatome; Zimmer, Warsaw, IN). Normal
skin obtained from 20 nonpsoriatic subjects who underwent surgical
procedures at the Department of Plastic Surgery at the Rambam
Medical Center, Haifa, was used for skin grafting in the mouse
model. The skin was obtained after we had secured informed
consent and IRB approval from the Rambam and Flieman Medical
Centers, and the study was performed in adherence with the
Declaration of Helsinki Principles.
Culture of cells to induce NK activity
PBMCs were isolated from 17 psoriatic donors via centrifugation
on Ficoll/Hypaque (Amersham Biosciences, Piscataway, NJ).
The PBMCs were then cultured with 100Uml1 IL-2 (Pepro Tech,
Rocky Hill, NJ) in medium composed of RPMI 1640, 10% human AB
serum (Sigma, St Louis, MO), 1% glutamine, and 1% antibiotics
(media components; Biological Industries, Kibbutz Beit Haemeck,
Israel). Medium was changed as needed. After 21 days, the cells
were injected into human skin explants on beige-SCID mice. In our
previous studies, such cell lines expressed heterogeneous NK cell
markers and exhibited NK cytotoxicity (Gilhar et al., 2002, 2006).
The NK cell lines demonstrated a mean of 38% of cells positive for
CD56 (Gilhar et al., 2006).
Phenotypic characterization of cells before and after culture
PBMCs from psoriasis donors were activated in culture with IL-2 as
described above. After 14 days, the cells were centrifuged and
stained for flow cytometric analysis. On the same day, whole blood
from a psoriatic donor was treated with ACK lysis buffer for
5minutes and then centrifuged at 2000 r.p.m. for 10minutes, and the
PBMCs were then stained for flow cytometric analysis.
Cells were stained with mouse anti-human CD3 (PE-Cy5, Becton
Dickinson, San Jose, CA); mouse anti-human CD56 (APC, Becton
Dickinson), and rabbit anti-human Kv1.3 (FITC, Alomone Labs,
Jerusalem, Israel). The lymphocyte population was gated and the
level of Kv1.3 was assessed in T cells (CD3þ ) and NK (CD56þ )
using FloJo software (Tree Star, Ashland, OR).
Skin transplantation and Kv1.3 blocking
Skin transplantation was performed as described previously (Gilhar
et al., 2006). Briefly, skin from a single donor was divided into two
segments and grafted onto two mice. NK cells were injected 4 weeks
after skin engraftment. NK cells were suspended in complete
medium (RPMI 1640, 10% human AB serum, 1% glutamine, 1%
antibiotics, 100Uml1 IL-2), at 107 cellsml1, and injected intra-
dermally in 0.7ml (7 106 cells). Four weeks after lymphocyte
injection (8 weeks after engraftment), the grafts were harvested.
Grafts were analyzed by histology and immunohistochemistry.
Blocking of Kv1.3 was performed via injections of 6-FAM-AEEAc-
ShK trifluoroacetate salt (Bachem AG, Bubendorf, Switzerland). ShK
(16.5mg/0.2ml for a graft) was injected, intradermally into each
graft, 14 days after the NK-like cell injections. The injections were
given for a period of 14 days. The dosage was given according to the
protocol of a previous study (Beeton et al., 2001b). Control mice
received PBS.
Immunohistochemical staining of frozen sections
Five-micrometer frozen tissue sections were fixed in acetone for
10minutes at 4 1C and then washed with PBS. Endogenous
peroxidase activity was inhibited, and samples were blocked for
nonspecific binding.
Primary antibodies were applied on the sections (mouse anti-
human CD3, mouse anti-CD16, and mouse anti-CD56, all from
Becton Dickinson; rabbit anti-KV1.3 from Alomone Labs; mouse
anti-human IFN-g (R&D Systems, Minneapolis, MN)) for 1 hour at
room temperature. Isotype controls were used for all primary
antibodies. After washing, slides were incubated with appropriate
secondary antibodies (biotinylated horse anti-mouse IgG (Vector
Labs, Burlingame, CA), and horseradish peroxidase–conjugated
donkey anti-rabbit IgG), followed by a wash and incubation with
streptavidin–horseradish peroxidase (Jackson ImmunoResearch,
West Grove, PA) for all the primary mouse antibodies. The markers
were revealed by treating sections with 3-amino-9-ethylecarbazole.
Samples were examined under light microscopy.
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Immunohistochemical staining of paraffin sections
Goat anti-human TNF-a (R&D Systems) and rabbit anti-CCR7
(Abcam, Cambridge, UK) were used on deparaffinized and
peroxidase-blocked sections.
Slides were subjected to antigen retrieval for 20minutes in a
microwave, cooled at room temperature for 25minutes, and
processed in the usual avidin biotin system. The wash buffer for
TNF-a was PBS-saponin and Tris-buffered saline-Tween for CCR7.
Analyses were performed using TINA 2.1 software (Raytest,
Straubenhardt, Germany).
Slides were evaluated blindly by experienced observers. The
fields of immunostained sections were presented randomly. The
positive cells in the dermal compartment were counted in an area of
0.015mm2. Thirty to 40 randomly chosen fields were analyzed for
each sample.
Determination of epidermal thickness
Histological assessment of the grafts was performed by light
microscopy as reported previously (Gilhar et al., 2006). Two blinded
observers performed the evaluation, including one who was
not aware of the design of the study. Epidermal thickness was
determined with an ocular micrometer at a minimum of 50 points
along the epidermis selected to represent points of maximal and
minimal thickness. Thickness of the suprapapillary plate was
similarly measured at 50 points for each sample
Statistical analysis
The results are presented as means±SDs. To compare the two
groups, we used either independent-samples t-tests (if the data were
normally distributed) or Mann–Whitney tests (when the data were
not normally distributed). The P-values presented are always for two-
tailed tests unless stated otherwise. We used 5% as the critical level
of significance. SPSS 17.0 (Chicago, IL) was used to analyze the data.
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